Charles Schwab Investment Management Inc. Boosts Stake in BioLife Solutions, Inc. (NASDAQ:BLFS)

Charles Schwab Investment Management Inc. raised its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 3.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 319,959 shares of the medical equipment provider’s stock after acquiring an additional 9,750 shares during the period. Charles Schwab Investment Management Inc.’s holdings in BioLife Solutions were worth $8,012,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Sequoia Financial Advisors LLC purchased a new position in BioLife Solutions in the 2nd quarter valued at about $466,000. Isthmus Partners LLC increased its stake in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares during the period. Mutual of America Capital Management LLC acquired a new position in shares of BioLife Solutions during the second quarter valued at approximately $8,592,000. Envestnet Asset Management Inc. increased its stake in shares of BioLife Solutions by 261.5% during the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after acquiring an additional 92,021 shares during the period. Finally, Legato Capital Management LLC bought a new stake in BioLife Solutions during the second quarter worth approximately $233,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Aby J. Mathew sold 17,604 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.05, for a total transaction of $352,960.20. Following the completion of the sale, the executive vice president now directly owns 284,442 shares of the company’s stock, valued at $5,703,062.10. The trade was a 5.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the sale, the executive now directly owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,313 shares of company stock valued at $1,572,899. Insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BLFS. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright cut their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $26.20 on Wednesday. The firm has a market cap of $1.22 billion, a PE ratio of -24.72 and a beta of 1.91. BioLife Solutions, Inc. has a 12 month low of $12.45 and a 12 month high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $24.49 and its two-hundred day moving average price is $23.47.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.